Why the study?
Alcohol septal ablation for obstructive HCM carries life-threatening complications, prompting evaluation of conduction defects and arrhythmia risk with alternative EVOH-DMSO septal ablation compared to other agents.
Does septal reduction therapy with EVOH-DMSO reduce LVOT gradient and what is the risk of conduction system defects in patients with symptomatic obstructive hypertrophic cardiomyopathy?
Observational (n=25)
No
Does septal reduction therapy with EVOH-DMSO reduce LVOT gradient and what is the risk of conduction system defects in patients with symptomatic obstructive hypertrophic cardiomyopathy?
EVOH-DMSO septal ablation effectively reduces LVOT gradient in obstructive hypertrophic cardiomyopathy but is associated with a significant risk of conduction system disturbances, particularly RBBB and complete AV block.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2023 study conducted an observational in Symptomatic obstructive hypertrophic cardiomyopathy (n=25). EVOH-DMSO septal ablation vs. Baseline was evaluated on Peak left ventricular outflow tract (LVOT) gradient (p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: